Urovant Sciences Inc. announced key data for GEMTESA® (vibegron) 75 mg to be presented at the 2021 Annual Meeting of the American Urological Association (AUA2021). GEMTESA was approved by the U.S. Food and Drug Administration for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency. The AUA21 podium presentation will examine new clinical trial data on the effect of GEMTESA on ambulatory blood pressure in OAB patients. A separate poster presentation will demonstrate its efficacy in patients with ‘dry’ overactive bladder (without urinary leakage), based on a post-hoc analysis of data from the pivotal EMPOWUR study. The conference will be held in person in Las Vegas, NV, and virtually, on September 10-13.